News Image

Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

Provided By GlobeNewswire

Last update: Mar 27, 2024

Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions

Continued success of Compassionate/Expanded Use Access Program demonstrates potential of MAT2203 in treating multiple severe invasive fungal infections, including invasive aspergillosis

Read more at globenewswire.com

MATINAS BIOPHARMA HOLDINGS I

NYSEARCA:MTNB (7/23/2025, 8:04:00 PM)

0.95

0 (-0.02%)



Find more stocks in the Stock Screener

Follow ChartMill for more